Effect of different folic acid doses on methotrexate-related toxicity and its association with erythrocyte methotrexate-polyglutamates in patients with rheumatic diseases: a single-center exploratory randomized controlled trial
Authors:
- Yusuke YoshidaYYYusuke Yoshida
- Yohei HosokawaYHYohei Hosokawa
- Takanori TaogoshiTTTakanori Taogoshi
- Naoya OkaNONaoya Oka
- Hiroki KobayashiHKHiroki Kobayashi
- Genki KidoguchiGKGenki Kidoguchi
- Kei ArakiKAKei Araki
- Michinori IshitokuMIMichinori Ishitoku
- Tomohiro SugimotoTSTomohiro Sugimoto
- Sho MokudaSMSho Mokuda
- Hiroaki MatsuoHMHiroaki Matsuo
- Shintaro HirataSHShintaro Hirata
Open Access
- 6 June 2026
- journal article
- Published by Springer Nature in Clinical Rheumatology
- Vol. 45 (7) , 3957-3965
Abstract
Introduction: Folic acid is routinely co-administered with methotrexate (MTX) to reduce toxicity; however, the optimal dose remains unclear. This study investigated whether increasing the weekly folic acid dose from 5 to 10 mg reduces MTX-related toxicity in patients receiving stable-dose MTX therapy. Methods: In this single-center, open-label, randomized controlled trial, 44 patients with rheumatic diseases on stable-dose MTX either received 10 mg (ARM-1) or 5 mg (ARM-2) of folic acid per week for 12 weeks. Liver damage, other MTX-related toxicities, and erythrocyte MTX-polyglutamate (MTX-PG) concentrations were compared between groups using logistic regression analysis or analysis of covariance. Japan Registry of Clinical Trials (number: jRCT1061230085). Results: Forty-two patients completed the study. The presence of liver damage at Day 84 did not differ significantly between the two groups (OR 0.41, 95% CI, 0.01–5.75, p = 0.506). Adjusted mean differences in aspartate transaminase and alanine transaminase at Day 84 between the groups were − 0.33 U/L (95% CI, − 2.68 to 2.02; p = 0.779) and − 0.44 U/L (95% CI, − 5.39 to 4.51; p = 0.859). Comparison of outcomes between groups at Day 84 showed no significant differences in any outcomes, except for fatigue severity (adjusted mean difference, − 0.87; 95% CI, − 1.71 to − 0.04; p = 0.041). Baseline fatigue was associated with baseline MTX-PG2 or MTX-PG1-2 concentrations (OR, 1.06; p = 0.049 or OR, 1.03; p = 0.040, respectively). Conclusions: Increasing folic acid dose to 10 mg/week showed little effect on reducing MTX-related toxicity, although it may improve fatigue in selected patients. Key Points • Increasing the weekly folic acid dose from 5 mg to 10 mg showed no additional benefit in reducing methotrexate-related toxicity in patients on stable-dose MTX. • Higher-dose folic acid was associated with improved fatigue severity, indicating a potential therapeutic option for patients who develop fatigue.Keywords
Funding Information
- JSPS KAKENHI (24K18642)
- TSUCHIYA MEMORIAL MEDICAL FOUNDATION
- Hiroshima University
This publication has 23 references indexed in Scilit:
- Japan College of Rheumatology guidance for the use of methotrexate in patients with rheumatoid arthritis: Secondary publicationModern Rheumatology, 2023
- Systematic review of recommendations on the use of methotrexate in rheumatoid arthritisClinical Rheumatology, 2020
- Usefulness of daily folic acid supplementation during methotrexate treatment of Japanese patients with rheumatoid arthritisModern Rheumatology, 2020
- Methotrexate and its mechanisms of action in inflammatory arthritisNature Reviews Rheumatology, 2020
- The REDCap consortium: Building an international community of software platform partnersJournal of Biomedical Informatics, 2019
- Methotrexate mechanism in treatment of rheumatoid arthritisJoint Bone Spine, 2019
- Folylpolyglutamate synthase is a major determinant of intracellular methotrexate polyglutamates in patients with rheumatoid arthritisScientific Reports, 2016
- Research electronic data capture (REDCap)—A metadata-driven methodology and workflow process for providing translational research informatics supportJournal of Biomedical Informatics, 2009
- Effect of folic or folinic acid supplementation on the toxicity and efficacy of methotrexate in rheumatoid arthritis: A forty-eight-week, multicenter, randomized, double-blind, placebo-controlled studyArthritis & Rheumatism, 2001
- The effect of folic acid supplementation on the toxicity of low‐dose methotrexate in patients with rheumatoid arthritisArthritis & Rheumatism, 1990